FDA发布降低输血传播乙肝病毒风险最终指南,适用全血及血浆采集检测
Recommendations for Reducing the Risk of Transfusion-Transmitted Hepatitis B Virus Guidance for Industry November 2026
FDA发布最终指南,建议采集全血和血液成分(含Source Plasma)的血液机构检测HBV,以降低输血传播风险。指南指出HBV属相关输血传播感染,对应21 CFR 610.40检测、610.41献血者延迟及630.40献血者通知要求。文件编号为FDA-2024-D-5942,公众可随时就该指南提交意见。
GUIDANCE DOCUMENT
Recommendations for Reducing the Risk of Transfusion-Transmitted Hepatitis B Virus Guidance for Industry November 2026
Final
- Docket Number:
- FDA-2024-D-5942
- Issued by:
-
Guidance Issuing Office
Center for Biologics Evaluation and Research
We, FDA, are providing you, blood establishments that collect blood and blood components, including Source Plasma, with recommendations for testing blood and blood components for hepatitis B virus (HBV) to reduce the risk of transfusion-transmitted HBV. The recommendations contained in this guidance apply to the collection of Whole Blood and blood components, including Source Plasma.
HBV is a relevant transfusion-transmitted infection (RTTI) (Title 21 of the Code of Federal Regulations (CFR) 630.3(h)(1)(ii)) and, therefore, subject to the testing requirements in 21 CFR 610.40, the donor deferral requirements in 21 CFR 610.41 and the donor notification requirements in 21 CFR 630.40.
Under 21 CFR 610.40(a)(1), an establishment that collects blood and blood components must test each donation of human blood or blood components for transfusion or for use in manufacturing a product, including donations intended as a component of, or used to manufacture, a medical device, for evidence of infection due to HBV. In addition, under 21 CFR 610.40(b), establishments must use, in accordance with the manufacturer’s instructions, one or more screening tests that FDA has licensed, approved or cleared as necessary to meet the testing requirement and to reduce adequately and appropriately the risk of transmission of RTTIs. This guidance provides recommendations for testing blood donations to reduce adequately and appropriately the risk of HBV transmission under these regulations.
Submit Comments
You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
If unable to submit comments online, please mail written comments to:
Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document's docket number: FDA-2024-D-5942.
Questions?
来源:FDA 官方药品与生物制品信息 · fda.gov